Atlas Trials

Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Clinical trial NCT03891355 · UNKNOWN

Trial details

NCT number
NCT03891355
Sponsor
Fondazione Italiana Linfomi - ETS
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2019-09-30
Primary completion
2020-12-04
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.